1Roger VL,Go AS,Lloyd-Jones DM. Heart disease and stroke statistics--2011 update:a report from the A-merican Heart Association[J].{H}CIRCULATION,2011,(4):e18-e209.
2Vaduganathan M,Gheorghiade M,Pang PS. Efficacy of oral tolvaptan in acute heart failure patients with hypo-tension and renal impairment[J].J Cardiovasc Med(Hag-erstown),2012,(7):415-422.
3Pang PS,Gheorghiade M,Dihu J. Effects of tolvap-tan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes:analysis from the efficacy of vasopressin antagonism in heart fail-ure outcome study with tolvaptan(Everest) trials[J].{H}American Heart Journal,2011,(6):1067-1072.
4Ekman I,Chassany O,Komajda M. Heart rate re-duction with ivabradine and health related quality of Life in patients with chronic heart failure:results from the SHIFT study[J].{H}EUROPEAN HEART JOURNAL,2011,(19):2395-2404.
5Vítovec J,Spinarová L,Spinar J. Effects of selective heart rate reduction with ivabradine on left ventricular remodel-ling and health related quality of Life:results from the SHIFT substudies[J].{H}Vnitrni Lekarstvi,2012,(7/8):612-617.
6Taylor J. The 2012 ESC guidelines on heart failure[J].{H}EUROPEAN HEART JOURNAL,2012,(14):1703-1704.
7Teerlink JR,Cotter G,Davison BA. Serelaxin,re-combinant human relaxin-2,for treatment of acute heart failure(RELAX-AHF):a randomised,placebo-controlled trial[J].{H}LANCET,2013,(9860):29-39.
8Cleland JG,Teerlink JR,Senior R. The effects of the cardiac myosin activator,omecamtiv mecarbil,on cardiac function in systolic heart failure:a double-blind,placebo-controlled,crossover,dose-ranging phase 2 trial[J].Lan-cet,2011,(9792):676-683.
9Horowitz JD,Rosenson RS,McMurray JJ. Clinical trials update AHA congress 2010[J].{H}Cardiovascular Drugs and Therapy,2011,(1):69-76.
